Cantourage Group SE has announced the launch of its first proprietary medical cannabis brand for the German market, in a meaningful pivot for the distributor.
The Berlin-listed company is expanding its operations to purchase flower outright, with its first two batches already allocated to pharmacies across the country under its new house brand, ‘Gramz’.
Its new venture, announced on July 15, comes as the German medical cannabis sector continues to reckon with a flood of cheap Canadian cannabis, saturating the market and piling pressure on the margins of local operators.
According to Statistics Canada data cited in Prohibition Partners’ Global Medical Cannabis Market Review 2026, Canadian exports of medical cannabis reached over 275 tonnes in 2025, more than 2.5 times the 107 tonnes shipped in 2024, and a jump of almost 170 tonnes in a single year. Canadian producers, boxed in by their own saturated domestic market and softening recreational margins, have found in Germany a release valve for excess production.
The volume has swamped the German wholesale channel. Data from Grünhorn shows the majority of medical flower products in the country now list under €8 per gram, with the heaviest concentration in the 20–25% THC band selling at €6–8/g. As of Q4 2025, more than 480 separate products carrying above 25% THC were priced in that €6–8 range. Where flower was routinely dispensed above €10/g in late 2023, that segment is now a shrinking corner of the market.
READ MORE…
The latest figures presented at the recent Business of Cannabis Intelligence Summit in Berlin, the average price of pharmacy flower fell 46% to €4.52/g in the 14 months to March 2026.
With this in mind, Cantourage’s move away from sharing revenues with its suppliers is something other distributors will be watching closely.
Cantourage built its business as an importer, using its ‘Fast Track Access’ platform to bring third-party growers’ flower into Germany on a revenue-share basis. For Gramz, it will buy the raw material outright and carry the inventory itself, keeping more of the margin on each gram sold rather than splitting it with the grower.
That change also widens Cantourage’s supplier pool, since it can source from growers who declined revenue-sharing deals, and gives it tighter control over which genetics, price points and batches carry the brand. Gramz is pitched as value-led premium flower for the self-pay market, built on the patient-preference data Cantourage has gathered across years of pharmacy sales.
“Sustainable brands are built when product quality, pricing and brand promise are fully aligned,” said Patrick Malessa, Director of Marketing at Cantourage GmbH. “Our objective was not simply to launch another brand, but to establish one that consistently delivers on its promise.”
Cantourage is leaning on premium products to lift profitability more broadly. First-quarter 2026 revenue rose 11% on the previous quarter to €20.6 million, its EBITDA margin reached 10.6% and it held net cash of €8.8 million, according to preliminary figures. Germany still accounts for the largest share of revenue at 51.5%, though the UK has climbed to 41.3%.
Cantourage expects further house-brand launches in the second half of 2026 and reports first-half results on 13 August, which will provide the first solid data on whether owning the flower, rather than merely moving it, delivers better margins.









